Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : License symbols : TEVJF save search
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
Published: 2024-01-19 (Crawled : 17:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 6.64%
H: 11.54%
C: 8.1%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.85%
H: 1.46%
C: 0.69%
avt02 avt04 license update
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
Published: 2023-10-12 (Crawled : 08:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.22%
H: 0.0%
C: -0.66%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.51%
H: 0.1%
C: -1.32%
avt04 license update application
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
Published: 2023-06-28 (Crawled : 23:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -6.26%
H: 4.93%
C: 0.15%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.74%
H: 1.12%
C: 0.19%
avt02 license update application
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
Published: 2023-06-12 (Crawled : 07:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.98%
H: 1.96%
C: -8.62%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.01%
H: 0.16%
C: -0.06%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.5%
H: 1.71%
C: 0.57%
avt04 stelara biosimilar license teva
Complete Response Letter Received for AVT02 Biologics License Application
Published: 2023-04-14 (Crawled : 08:00) - biospace.com/
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -14.46%
H: 0.0%
C: -8.97%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -7.13%
H: 1.05%
C: -3.6%
avt02 license application response
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
Published: 2023-04-14 (Crawled : 01:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -14.46%
H: 0.0%
C: -8.97%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.0%
H: 0.85%
C: -2.34%
avt02 license update application
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Published: 2023-01-06 (Crawled : 10:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 5.27%
H: 4.54%
C: 1.42%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.74%
H: 0.44%
C: 0.07%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.68%
H: 3.69%
C: 3.21%
avt04 stelara biosimilar teva application license
Alvotech Reports Update on Initial AVT02 Biologics License Application
Published: 2022-09-05 (Crawled : 10:00) - globenewswire.com
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
| Email alert
Add to watchlist
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
avt02 application license update
U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19
Published: 2022-04-14 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.34%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.56%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.05%
H: 0.92%
C: 0.11%
covid-19 cov treatment fda application license review
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
Published: 2021-11-25 (Crawled : 18:00) - globenewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
israel quantum genomics genomic license
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
Published: 2021-10-26 (Crawled : 21:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
disease neurodegenerative collaboration oda drug license
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.